Compare Franklin Resources, Inc. (BEN) vs Charles River Laboratories Intl. Inc (CRL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Franklin Resources, Inc. vs Charles River Laboratories Intl. Inc — how do they compare? Franklin Resources, Inc. trades at $33.37 (market cap $16.95B), while Charles River Laboratories Intl. Inc trades at $288.87 (market cap $13.46B). The key difference: Franklin Resources, Inc. is the larger of the two by market cap, and Franklin Resources, Inc. pays a 3.96% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| BEN | CRL | |
|---|---|---|
Market Cap | $16.95B | $13.46B |
Sector | Financials | Health |
52-Week High | $35.77 | $282.00 |
52-Week Low | $21.18 | $145.57 |
Enterprise Value | $29.90B | $16.30B |
Dividend Yield | 3.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Franklin Resources (BEN) trades at $33.59, up 0.21% on the day, with a bullish technical signal and consistent earnings beats. The company reported record AUM of $1.80 trillion as of July 31, 2026 (Business Wire, 2026-08-05), driven by strong inflows and diversification. Fundamentals show revenue growth to $8.77B in 2025 and a net income margin of 5.98%, though ROE remains low at 1.34%.
The outlook is positive with a consensus price target of $36.50 (22 analysts, August 2026) and recent momentum from private markets expansion. Key risks include volatile cash flows, with a net cash outflow of $835M in 2025, and competitive fee pressures. The stock offers upside potential but requires monitoring of margin sustainability and market-sensitive AUM growth.
Charles River Laboratories (CRL) trades at $284.37, up 2.66% today and near its 52-week high, reflecting strong bullish momentum. The stock has consistently beaten earnings estimates in recent quarters, including a Q2 2026 EPS of $3.02 versus $2.77 expected, and the company raised its full-year guidance. Despite negative net income margins, operating cash flow remains robust at $738 million in 2025. Analyst sentiment is overwhelmingly positive with 26 buy ratings and a consensus price target of $277.29.
The outlook is supported by improving biotech demand and cost controls, but high valuation multiples and recent insider selling pose risks. Earnings growth and margin expansion are key catalysts, though profitability challenges and macroeconomic sensitivity could pressure the stock. Investors should weigh strong technicals and analyst support against fundamental weaknesses and execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Franklin Resources, Inc.
Franklin Resources provides investment services for individual and institutional investors. At the end of August 2022, Franklin had $1.388 trillion in managed assets, composed primarily of equity (32%), fixed-income (38%), multi-asset/balanced (10%) funds, alternatives (16%), and money market funds (4%). Distribution tends to be weighted more toward retail investors (49% of AUM) investors, as opposed to institutional (49%) and high-net-worth (2%) clients. Franklin is also one of the more global firms of the U.S.-based asset managers with more than 35% of its AUM invested in global/international strategies and 25% of managed assets sourced from clients domiciled outside the United States.
Read more on BEN →About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →
